Moderna is testing a norovirus vaccine in a phase three trial with results expected as soon as this year. The trial is enrolling ahead of schedule, driven by a spike in norovirus cases this winter. While the vaccine targets specific norovirus genotypes, researchers hope it may offer broader protection. Moderna aims to reduce the severity of norovirus illness and prevent complications, particularly in vulnerable populations like seniors.
Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year.
"I don't know if it's directly attributable to the increased incidence of norovirus this season, but we clearly have a lot of interest in participation in this trial," Fink said. Moderna's vaccine candidate targets the three genotypes that the company says typically cause most infections. It works by showing the immune system something that looks like norovirus but isn't infectious, so the body can learn how to fight back if the real thing hits.
The company sees the main opportunity in vaccinating seniors who are particularly vulnerable to norovirus complications like dehydration. People 65 and up make up the majority of the estimated 900 Americans who die from norovirus complications in the U.S., according to the CDC.
NOVOVIRUS VACCINE MODERNA CLINICAL TRIAL PUBLIC HEALTH
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna Launches Phase III Trial for Norovirus VaccineModerna has embarked on a large-scale Phase III trial to test the efficacy of its norovirus vaccine candidate. The trial, which will involve 25,000 volunteers worldwide, aims to determine the vaccine's ability to prevent infection and reduce the severity of symptoms associated with norovirus, a common cause of food poisoning.
Read more »
Moderna Norovirus Vaccine Trial Shows Promise Amidst Winter SurgeModerna's phase three trial for a norovirus vaccine is underway, with results expected soon. The highly contagious stomach bug is on the rise, and the vaccine could offer protection for vulnerable populations.
Read more »
Moderna Norovirus Vaccine Trial Shows Promise in Combating Winter SurgeModerna is running a large-scale phase three trial of its norovirus vaccine, with results expected as soon as late 2023 or 2026. This comes at a crucial time as norovirus cases rise sharply this winter, exceeding 30% by December.
Read more »
Moderna Races to Develop Norovirus Vaccine Amidst Rising CasesModerna is testing a norovirus vaccine in a large phase three trial, with results expected as early as this year. The development comes as norovirus cases surge, with outbreaks already up over 30% by December. This highly contagious virus is a particular threat to seniors. The vaccine candidate targets the three most common norovirus genotypes and aims to reduce the severity of symptoms and hospitalizations.
Read more »
Moderna's Norovirus Vaccine in Late-Stage Trials, Offering Hope for Winter IllnessModerna is advancing a norovirus vaccine through a pivotal phase three trial, with results expected as early as this year. This comes as norovirus cases surge this winter, prompting optimism for a potential solution to this highly contagious and debilitating illness.
Read more »
Tucson Research Center on Track to Develop Norovirus VaccineThe Quality of Life Research Center in Tucson is leading a phase three clinical trial to develop a vaccine for the highly contagious norovirus, which causes millions of illnesses and hundreds of deaths annually.
Read more »